AUTHORS
Bruce Kamich
Bruce Kamich is TheStreet's in-house technical analyst with a 43 year career with a number of bulge bracket firms like Morgan Stanley, Smith Barney Harris Upham, and Merrill Lynch. Along the way he accumulated knowledge about the fundamentals of the commodity markets, interest rates, equities and ETFs.
In addition to writing for theStreet.com Kamich has been teaching technical analysis at Baruch College for the past twenty years.
Kamich was one of the earliest Chartered Market Technicians or CMTs, a professional designation similar to the CFA title. He has authored two books on charting and technical analysis - "How Technical Analysis Works" and "Chart Patterns." He is a two-time past president of the Market Technicians Association (now called the CMTA), the professional organization for chartists worldwide. He was also the president of the Market Technicians Association Educational Foundation (MTAEF.org).
In addition to writing for theStreet.com Kamich has been teaching technical analysis at Baruch College for the past twenty years.
Kamich was one of the earliest Chartered Market Technicians or CMTs, a professional designation similar to the CFA title. He has authored two books on charting and technical analysis - "How Technical Analysis Works" and "Chart Patterns." He is a two-time past president of the Market Technicians Association (now called the CMTA), the professional organization for chartists worldwide. He was also the president of the Market Technicians Association Educational Foundation (MTAEF.org).
Recent Articles By The Author
VMware Charts Suggest More Weakness Ahead
The technical indicators of the information technology company are not encouraging at present.
Paychex Could Correct Lower in the Weeks Ahead
The longer-term trend is positive so this anticipated decline could become a buying opportunity.
Norwegian Cruise Line Is Headed Back to Port
We don't see signs of smooth sailing right now.
FedEx Has Started a Correction so Don't Fight the Tape
Look for FDX to be on the defensive until the middle of February.
NovoCure Could Weaken Further in the Days Ahead
Let's check out the charts and indicators again.
QuantumScape Plunges but Is the Damage Over?
Time for another look at the shares as we start 2021.
The Correction in AstraZeneca Could Be Nearing an End
Aggressive traders might want to look past any near-term price weakness and consider a small long position.
Oops!
We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.
Please Join or Log In to Email Our Authors.
Email Real Money's Wall Street Pros for further analysis and insight
Already a Subscriber? Login